The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
M. Thomas
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Research Funding - Roche
A. Reuss
No relevant relationships to disclose
J. R. Fischer
No relevant relationships to disclose
S. Andreas
No relevant relationships to disclose
C. Kortsik
No relevant relationships to disclose
C. Grah
No relevant relationships to disclose
M. H. Serke
No relevant relationships to disclose
M. von Eiff
No relevant relationships to disclose
C. Witt
No relevant relationships to disclose
J. Kollmeier
No relevant relationships to disclose
E. Müller
No relevant relationships to disclose
L. Müller
No relevant relationships to disclose
M. Schenk
No relevant relationships to disclose
R. Heine
No relevant relationships to disclose
D. M. Behringer
No relevant relationships to disclose
M. Schroeder
No relevant relationships to disclose
N. Reinmuth
No relevant relationships to disclose
P. Schnabel
No relevant relationships to disclose
T. Acker
No relevant relationships to disclose
M. Wolf
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Research Funding - Roche